In addition to excessive daytime sleepiness, up to 60% of narcolepsy cases include cataplexy, which is a sudden loss of muscle control. When patients experience intense emotion, either positive or ...

For people living with narcolepsy, no amount of sleep alleviates the feeling of being tired. While most people are either awake or asleep, narcolepsy feels as if you're never really in either state.

The multi-centre, two-period Phase III trial sought to evaluate the long-term efficacy and safety of AXS-12 in patients with both narcolepsy and cataplexy. The trial comprised a six-month open ...

Idiopathic hypersomnia is a chronic sleep-wake disorder that causes you to feel excessively sleepy during the day, even with a full night’s sleep. Most people experience daytime sleepiness at ...

On October 16, 2024, LUMRYZ was additionally approved as a once-at-bedtime treatment for cataplexy or EDS in patients 7 years of age and older with narcolepsy. The FDA approval of LUMRYZ was supported ...

Samelisant (SUVNG-3031) is under development for the treatment of narcolepsy with and without cataplexy and cognitive disorders. The drug candidate is administered orally in the form of tablet. The ...

There are two types of narcolepsy, and both cause EDS. Most people with Type 1 (with cataplexy — the sudden loss of muscle tone explained above) have low levels of the brain hormone hypocretin ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III trial. AXS-12 (reboxetine), the norepinephrine reuptake inhibitor and ...